Biogen (BIIB) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended marketing authorization in the European Union for Zurzuvae to treat postpartum depression.
Biogen and Sage Therapeutics (SAGE), which discovered Zurzuvae, agreed in 2020 to jointly develop and commercialize Zurzuvae in the US. Under the deal, Biogen has exclusive rights to develop and commercialize Zurzuvae outside of the U.S., excluding Japan, Taiwan, and South Korea.
Biogen said the recommendation for Zurzuvae will now be reviewed by the European Commission for marketing authorization in the European Union. It said it expects a decision to be made in Q3.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。